Graminex Signs Agreement with Sloan-Kettering

Graminex Signs Agreement with Sloan-Kettering

SAGINAW, Mich.Graminex LLC signed a confidentiality agreement with New Yorks Memorial Sloan-Kettering Cancer Center to conduct research with Graminex Flower Pollen Extract. The agreement will allow Sloan-Kettering the ability to determine health effects of the material, which has been studied clinically for anti-tumor, antiinflammatory and detoxification properties.

This agreement demonstrates Graminexs firm commitment to research and development of our pollen extracts, said Cynthia R. May, chief executive officer of Graminex (www.graminex.com). By partnering with Sloan-Kettering, a world leader in research, Graminex continues to show that the companys focus is in the area of research and product development.